Response to "Post-marketing strategies for medicine''

被引：0
|
作者：
Goldhammer, A. [1 ]
机构：
[1] Pharmaceut Res & Manufacturers Amer, Washington, DC USA
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2008年 / 83卷 / 01期
关键词：
D O I：
10.1038/sj.clpt.6100444
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：25 / 25
页数：1
相关论文
共 50 条
  • [41] Utilization of the smoking cessation medicine varenicline: an intensive post-marketing study in New Zealand
    Harrison-Woolrych, Mira
    Ashton, Janelle
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2010, 19 (09) : 949 - 953
  • [42] Methodological approaches to developing and establishing the body of evidence on post-marketing chinese medicine safety
    Liao Xing
    Robinson, Nicola
    CHINESE JOURNAL OF INTEGRATIVE MEDICINE, 2013, 19 (07) : 494 - 497
  • [43] Methodological approaches to developing and establishing the body of evidence on post-marketing chinese medicine safety
    Xing LIao
    Nicola Robinson
    Chinese Journal of Integrative Medicine, 2013, 19 : 494 - 497
  • [44] REVIEW OF TRANSPORTER-RELATED POST-MARKETING REQUIREMENT (PMR)/POST-MARKETING COMMITMENT (PMC) STUDY REPORTS.
    Fan, Y.
    Agarwal, S.
    Zhang, L.
    Lesko, L. J.
    Huang, S.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2011, 89 : S37 - S37
  • [45] Post-marketing surveillance of escitalopram in depressed outpatients
    Möller, HJ
    Lotze, K
    Lange, S
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2005, 15 : S428 - S428
  • [46] The consequences of drug misuse on post-marketing surveillance
    Schifano, Fabrizio
    Papanti, Gabriele Duccio
    Orsolini, Laura
    Corkery, John Martin
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2016, 9 (07) : 867 - 871
  • [47] Challenges and perspectives in surveillance of post-marketing/use
    Fontenele Martins, Mary Anne
    Coelho Penna Teixeira, Ana Paula
    VIGILANCIA SANITARIA EM DEBATE-SOCIEDADE CIENCIA & TECNOLOGIA, 2019, 7 (04): : 3 - 9
  • [48] Development of the Post-Marketing Requirements (PMR) Database
    Mouchet, Julie
    Albrieux, Marine
    Maier, Will
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2012, 21 : 218 - 218
  • [49] DEVELOPMENT OF A REGULATORY POST-MARKETING STUDIES DATABASE
    Caron, M.
    Mouchet, J.
    Emery, M. P.
    Longin, J.
    Maier, W. C.
    VALUE IN HEALTH, 2009, 12 (03) : A24 - A24
  • [50] Ibrutinib: A post-marketing safety analysis.
    Elias, Rawad
    Pudusseri, Anita
    Akinboro, Oladimeji
    White, Paul S.
    Sarosiek, Shayna
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
12345